Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo

Peptides

Volumn 19, Issue 7, 1998, Pages 1241-1248

  Kennedy, Brian P ^a   Mahata, Sushil K ^a   O'Connor, Daniel T ^a   Ziegler, Michael G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood pressure; Catecholamine; Catestatin; Chromaffin granule; Chromogranin A; Histamine

Indexed keywords

ADRENALIN; CATESTATIN; CHROMOGRANIN A; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CATECHOLAMINE RELEASE; HISTAMINE RELEASE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; VASODILATATION;

ADRENERGIC ANTAGONISTS; AMINO ACID SEQUENCE; ANIMALS; BLOOD PRESSURE; CHROMOGRANIN A; CHROMOGRANINS; ELECTRIC STIMULATION; EPINEPHRINE; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HYDROXYZINE; MALE; MOLECULAR SEQUENCE DATA; NEUROPEPTIDE Y; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PHENOXYBENZAMINE; PROPRANOLOL; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032122494     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(98)00086-2     Document Type: Article

References (30)

1. Champion H.C., Kadowitz P.J. Vasodilator responses to acetylcholine, bradykinin, and substance P are mediated by a TEA-sensitive mechanism. Am. J. Physiol. 273:1997;R414-R422.
2. + ATP channels mediate vasodilator responses to histamine in the cat. Am. J. Physiol. 273:1997;H928-H937.
3. Champion H.C., Murphy W.A., Coy D.H., Kadowitz P.J. Proadrenomedullin NH2-terminal 20 peptide has direct vasodilator activity in the cat. Am. J. Physiol. 272:1997;R1047-R1054.
4. Choi A.Y., Cahill A.L., Perry B.D., Perlman R.L. Histamine evokes greater increases in phosphatidylinositol metabolism and catecholamine secretion in epinephrine-containing than in norepinephrine-containing chromaffin cells. J. Neurochem. 61:1993;541-549.
5. Choi A.Y., Fukui H., Perlman R.L. Glucocorticoids enhance histamine-evoked catecholamine secretion from bovine chromaffin cells. J. Neurochem. 64:1995;206-212.
6. Cross L.J., Beck-Sickinger A.G., Bienert M., Gaida W., Jung G., Krause E., Ennis M. Structure activity studies of mast cell activation and hypotension induced by neuropeptide Y (NPY), centrally truncated and C-terminal NPY analogs. Br. J. Pharmacol. 117:1996;325-332.
7. Devillier P., Drapeau G., Renoux M., Regoli D. Role of the N-terminal arginine in the histamine-releasing activity of substance P, bradykinin and related peptides. Eur. J. Pharmacol. 168:1989;53-60.
8. Emadi-Khiav B., Mousli M., Bronner C., Landry Y. Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli. Eur. J. Pharmacol. 272:1995;97-102.
9. Eisenberg D., Weiss R.M., Terwilliger T.G. The hydrophobic moment detects periodicity in protein hydrophobicity. Proc. Natl. Acad. Sci. USA. 81:1984;140-144.
10. Fahmy N.R., Soter N.A. Effects of trimethaphan on arterial blood histamine and systemic hemodynamics in humans. Anesthesiology. 62:1985;562-566.
11. Galindo E.; Rill A.; Bader M. F.; Aunis D. Chromostatin, a 20-amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion. Proc. Natl. Acad. Sci. 88:1426-1430; 1991 [published erratum appears in Proc. Natl. Acad. Sci. USA. 91:832; 1994].
12. Garcia G.E., Gabbai F.B., O'Connor D.T., et al. Does chromostatin influence catecholamine release or blood pressure in vivo? Peptides. 15:1994;195-197.
13. Katoh F.K., Kitamura H., Niina R., et al. Proadrenomedullin N-terminal 20 peptide (PAMP), an endogenous anticholinergic peptide its exocytotic secretion and inhibition of catecholamine secretion in adrenal medulla . J. Neurochem. 64:1995;459-461.
14. Kennedy B., Shen G.H., Ziegler M.G. Neuropeptide Y-mediated pressor responses following high-frequency stimulation of the rat sympathetic nervous system. J. Pharmacol. Exp. Ther. 281:1997;291-296.
15. Kennedy B., Ziegler M.G. A more sensitive and specific radioenzymatic assay for catecholamines. Life Sci. 47:1990;2143-2154.
16. Lands A.M., Arnold A., McAuliff J.P., Luduena F.P., Brown T.G. Differentiation of receptor systems activated by sympathomimetic amines. Nature (London). 214:1967;597-598.
17. Livett B.G., Marley P.D. Noncholinergic control of adrenal catecholamine secretion. J. Anat. 183:1993;277-289.
18. Macquin-Mavier I., Clerici C., Franco-Montoya M.L., Harf A. Mechanism of histamine-induced epinephrine release in guinea pig. J. Pharmacol. Exp. Ther. 247:1988;706-709.
19. Mahata S.K., Mahata M., Yoo S.H., et al. A novel, catecholamine release-inhibitory peptide from chromogranin A: Autocrine control of nicotinic cholinergic-stimulated exocytosis. Adv. Pharmacol. 42:1998;260-264.
20. Mahata S.K., O'Connor D.T., Mahata M., et al. Novel autocrine feedback control of catecholamine release: a discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J. Clin. Invest. 100:1997;1623-1633.
21. Mousli M.; Landry Y. Role of postive charges of neuropeptide Y fragments in mast cell activation. Agents and Actions. 41 Spec No: C41-C42; 1994.
22. O'Connor D.T., Frigon R.P. Chromogranin A, the major catecholamine storage vesicle soluble protein. J. Biol. Chem. 259:1984;3237-3247.
23. 3 from rat peritoneal mast cells. J. Pharmacol. Exp. Ther. 243:1987;317-321.
24. Shimosawa T., Ando K., Fujita T. A newly identified peptide, proadrenomedullin N-terminal 20 peptide, induces hypotensive action via pertussis toxin-sensitive mechanisms. Hypertension. 30:1997;1009-1014.
25. Shimosawa T., Fujita T. Hypotensive effect of a newly identified peptide, proadrenomedullin N-terminal 20 peptide. Hypertension. 28:1996;325-329.
26. Simon J.P., Bader M.F., Aunis D. Secretion from chromaffin cells is controlled by chromogranin A-derived peptides. Proc. Natl. Acad. Sci. USA. 5:1988;1712-1716.
27. Staszewska-Barczak J., Vane J.R. The release of catechol amines from the adrenal medulla by histamine. Br. J. Pharmacol. 25:1965;728-742.
28. Taylor P. Agents acting at the neuromuscular junction and autonomic ganglia. Hardman J.G., Limbird L.E. Pharmacological basis of therapeutics. 9th ed. 1996;177-197 McGraw Hill, New York.
29. Zabludowski J., Clark S., Ball S.G., et al. Pressor effects of brief and prolonged infusions of epinephrine in the conscious rat. Am. J. Physiol. 246:1984;H683-H689.
30. 2+ fails to trigger exocytosis. J. Neurochem. 65:1995;12971308.